• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Hematology

Ibrutinib plus Venetoclax show promising results for first-line treatment of chronic lymphocytic leukemia

byAndréa Rondeau-BrownandAlex Chan
June 17, 2021
in Hematology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Evidence Rating Level: 2 (Good) 

1. Combination therapy of Ibrutinib and Venetoclax may be successful first-line treatments for patients with Chronic Lymphocytic Leukemia (CLL) who are currently not undergoing treatment 

2. This combination therapy had a 3-year progression free survival (PFS) of 93% in first line treatment of CLL 

The evolution and treatment of chronic lymphocytic leukemia (CLL) presents a clinical burden on the healthcare system causing a need for treatment plans to rapidly evolve in order to control the condition. The main form of treatment has shifted away from chemoimmunotherapy and towards oral targeted medications. However, success rates and durability of CLL treatment requires further research, particularly when comparing monotherapy to combined therapies. This study looked specifically at Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor as well as Venetoclax, a Bcl-2 inhibitor. These drugs have been used primarily in monotherapy leading to partial but not full remission of CLL. This nonrandomized phase 2 trial aimed to better understand the synergy of the two drugs by assessing remission and durability of CLL when combining the two medications. The study did this by assessing the measurable residual disease (MRD) in patients taking these medications together. While patients underwent cycles of treatment, this MRD was monitored in the bone marrow using peripheral blood samples taken every 6 months. More specifically, the study was a phase 2, non randomized trial conducted with patients currently not undergoing CLL treatment. The participants in the study had either del(17p), TP53-mutated CLL, del(11q), unmutated immunoglobulin heavy chain variable gene, or were aged 65 or older. In total, 75 patients taking combination therapy of Ibrutinib and Venetoclax were included in the study between August 2016 and June 2018. Serial assessments of their bone marrow were performed to achieve undetectable MRD remission (U-MRD).  Overall, 75% of the baseline cohort (n=60) reached U-MRD remission during the study period. Furthermore, the estimated 3-year progression free survival (PFS) rate was 93% (95% CI, 88%-99%) with an overall survival rate of 96% (95% CI, 92%-100%). While patients had variable outcomes, remission rates and PFS rates, the study found that no participants had CLL progression while taking the combined therapy. The study results focused on the impact of the combined therapy on CLL, however it is worth noting that participants had side effects, adverse events, complications, and one possible treatment-associated death was reported.  Overall, this study reveals that further research is required to better understand the long-term effects of combined treatment with Ibrutinib and Venetoclax as this study had a relatively short follow up period of only 38.5 months.

Click to read the study in JAMA Oncology

Image: PD

RELATED REPORTS

Minimally invasive surgery is beneficial for epithelial ovarian cancer 

Breast cancer survivors may have a lower risk of Alzheimer’s dementia

Abbreviated MRI is superior to whole-breast ultrasound for detection of cancer in dense breasts

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hematologyleukemiaoncology
Previous Post

2 Minute Medicine Rewind June 14, 2021

Next Post

Half of Ontario, Canada psychiatric emergency patients not previously seen in outpatient mental health

RelatedReports

All Specialties

Minimally invasive surgery is beneficial for epithelial ovarian cancer 

July 4, 2025
Chronic Disease

Breast cancer survivors may have a lower risk of Alzheimer’s dementia

July 2, 2025
3D mammography (tomosynthesis) enhances accuracy of breast cancer screening
Chronic Disease

Abbreviated MRI is superior to whole-breast ultrasound for detection of cancer in dense breasts

June 25, 2025
Lessons from real-world implementation of lung cancer screening
AI Roundup

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

June 10, 2025
Next Post
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Half of Ontario, Canada psychiatric emergency patients not previously seen in outpatient mental health

#VisualAbstract: Ziltivekimab antagonism of IL-6 reduces inflammation and thrombosis in patients with atherosclerotic risk factors

#VisualAbstract: Voclosporin shows clinical promise for treatment of active lupus nephritis

Cognitive outcomes in children of pregnant women with epilepsy

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.